Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
384,385 The CAPItello-291 phase 3 study indicates that regardless of AKT pathway abnormalities, the capivasertib plus fulvestrant group demonstrates a significant advantage in median PFS compared to the placebo plus fulvestrant group
Aapro MS, Bohlius J, Cameron DA., et al
Healthcare workers, athletes, and patients, among others, use sterile solutions to help with irrigation, injections, and medication delivery
PubMed 10
Finn PF, Dice JF
US$ 27.58
US$ 28.04
US$ 21.63
US$ 21.37
US$ 26.96
US$ 26.05
